Teva Pharmaceutical Industries (TEVJF) Total Debt (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Total Debt across 18 years of filings, most recently posting $16.6 billion for Q1 2026.

• Quarterly Total Debt changed 0.14% year-over-year to $16.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.6 billion (changed 0.14% YoY) and the FY2025 annual result came in at $16.8 billion, down 5.49% from the prior year.
• Total Debt retreated to $16.6 billion in Q1 2026, from $16.8 billion in the prior quarter.
• Over five years, Total Debt peaked at $22.9 billion in Q1 2022 and troughed at $16.6 billion in Q1 2026.
• A 5-year average of $19.3 billion and a median of $19.6 billion in 2024 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2025 — Total Debt decreased 15.24% — and 2026, when it declined 0.14%.
• Tracing TEVJF's Total Debt over 5 years: stood at $21.2 billion in 2022, then decreased by 6.5% to $19.8 billion in 2023, then decreased by 10.34% to $17.8 billion in 2024, then decreased by 5.49% to $16.8 billion in 2025, then decreased by 1.07% to $16.6 billion in 2026.
• Business Quant data shows TEVJF's Total Debt at $16.6 billion in Q1 2026, $16.8 billion in Q4 2025, and $16.8 billion in Q3 2025.